FDA issued an emergency use authorization (EUA) on Friday, December 11, for the Pfizer/BioNTech COVID-19 vaccine, which is indicated for those ages 16 years and older. CDC’s Advisory Committee on Immunization Practices (ACIP) gave the vaccine its official recommendation on Saturday, December 12, and finalized its endorsement to prioritize COVID-19 vaccination for health care workers—including pharmacists—and residents of long-term-care facilities with the limited supply that will be available initially.

The Vaccines and Related Biological Products Advisory Committee is likely to recommend today that FDA approve a COVID-19 vaccine developed by Pfizer and BioNTech.

FDA's vaccine advisory panel on Thursday voted 17-4 to recommend regulatory emergency authorization of Pfizer and BioNTech's COVID-19 vaccine, which the agency is expected to push forward within a matter of days.

The Vaccines and Related Biological Products Advisory Committee is likely to recommend today that FDA approve a COVID-19 vaccine developed by Pfizer and BioNTech.

New analyses of Pfizer and BioNTech's coronavirus vaccine indicate strong protection against COVID-19 within about 10 days of the first dose, much sooner than initially thought. Efficacy is about 52% with the first dose, then reaches about 95% with the second, the evidence shows.